
Disease−free survival
Variable
Events/N*
Univariable Hazard Ratio and 95% CI
Nodal Involvement
N0 103/236 0.50 (0.34−0.75)
N+ 14/24 1.13 (0.39−3.28)
Planned chemotherapy type
Gemcitabine−Cisplatin 69/161 0.53 (0.33−0.86)
Gemcitabine−Carboplatin 48/99 0.58 (0.33−1.03)
Microscopic margin status
Positive 15/31 0.37 (0.13−1.05)
Negative 102/229 0.56 (0.38−0.83)
Tumour Stage
T2 24/74 1.04 (0.45−2.37)
T3/T4 93/186 0.49 (0.32−0.74)
Primary Tumour Location
Ureter 46/89 0.59 (0.33−1.06)
Renal pelvis 36/92 0.59 (0.30−1.14)
Both 34/78 0.46 (0.23−0.94)
Number of lesions
1 99/221 0.56 (0.37−0.83)
>1 14/31 0.85 (0.29−2.44)
Overall 117/260 0.55 (0.38−0.80)
0.12 0.25 0.50 1.0 2.0
Favours Chemotherapy
Favours Surveillance


Overall survival
Variable
Events/N*
Univariable Hazard Ratio and 95% CI
Nodal Involvement
N0 93/236 0.67 (0.44−1.01)
N+ 13/24 0.80 (0.27−2.38)
Planned chemotherapy type
Gemcitabine−Cisplatin 57/161 0.57 (0.33−0.97)
Gemcitabine−Carboplatin 49/99 0.87 (0.50−1.53)
Microscopic margin status
Positive 18/31 0.96 (0.38−2.47)
Negative 88/229 0.61 (0.40−0.94)
Tumour Stage
T2 19/74 0.89 (0.36−2.21)
T3/T4 87/186 0.70 (0.46−1.08)
Primary Tumour Location
Ureter 43/89 0.72 (0.40−1.32)
Renal pelvis 32/92 0.67 (0.33−1.36)
Both 30/78 0.61 (0.29−1.28)
Number of lesions
1 91/221 0.70 (0.46−1.06)
>1 11/31 0.78 (0.24−2.55)
Overall 106/260 0.68 (0.46−1.00)
0.25 0.35 0.50 0.71 1.0 1.41 2.0 2.83
Favours Chemotherapy
Favours Surveillance